News

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

The Pharmacology and Therapeutics Special Interest Section was started to meet an unmet need of in-depth education and understanding in the ever-expanding pharmacotherapy advances in headache medicine.

Headache: The Journal of Head and Face Pain is recruiting a new class of trainees to join its Editorial Board through the Assistant Editor Team Program.

As the Overall Special Interest Section (SIS) Chair, Chair of the Post-traumatic Headache Section, and member of the Education, Leadership Development, and Scientific Program Committees, it is an honor to serve the Society.

I never intended to become a migraine specialist, let alone specialising in hormonal aspects of migraine, but curiosity about a condition that so little was known about, yet resulted in such significant disability, became an obsession as I wanted to find answers to the problems.

Headache centers are a thing?” That was the first thought that came to mind on a cold day around the turn of the century

As an American citizen growing up outside of the United States (mainland), I do not recall celebrating Hispanic Heritage month with particular fervor.

I am honored to be a Member-at-Large serving on the American Headache Society’s Board of Directors.

Meet Cynthia E. Armand, MD, Diversity, Equity, and Inclusion (DEI) Taskforce Co-Chair

Meet Claire Sandoe, MD, MS, Next Generation Migraine Therapies (NGMT) Program Co-Chair

Meet Gretchen E. Tietjen, MD, Recipient of the 2022 Lifetime Achievement Award

Meet Marcela Romero Reyes, DDS, PhD, FAHS

Meet Adam S. Sprouse Blum, MD

Meet Amaal J. Starling, MD, FAHS, FAAN